Xenbase Image ID: 77518

Fig. 5. Activation of Otx2 target genes is required for trigeminal placode specification. (A), (B) Otx2-EnR inhibits Runx3 at stage 23 ((A); 59%, n=26; arrowhead: trigeminal placode on uninjected side). This is rescued by co-injection of Otx2 ((B) inhibition reduced to 17%, n=36). Inserts show higher magnification of the trigeminal region. (C), (D) At stage 28 the profundal and trigeminal placodes can be distinguished; both are reduced after Otx2-EnR injection (78%, n=18). Compare control (C) and injected side (D). (E), (F) Injection of Gbx2 splice and translation blocking morpholinos ((F) 0% affected, n=25) does not affect Runx3; compare uninjected (E) and injected side (F). (G), (H). Injection of Gbx2-EnR does not affect Runx3 ((H); 3% affected, n=31); compare control (G) and injected side (H). (I)–(K) Activation of Otx2-EnR-GR at stage 10 inhibits Pax3 the profundal placode ((J) 49%, n=33); no change is observed without DEX ((I) 5% affected, n=61; PR: profundal placode) or when added at stage 14 ((K) 5% affected, n=42). Magnifications show profundal region (dotted outline) on the uninjected (top) and injected side (bottom; FDX: turquoise). All embryos were injected into the A3 blastomere at the 32-cell stage. Image published in: Steventon B et al. (2012) © 2012 Elsevier Inc. This image is reproduced with permission of the journal and the copyright holder. This is an open-access article distributed under the terms of the Creative Commons Attribution license Gene Synonyms Species Stage(s) Tissue runx3.L aml2, cbfa3, pebp2ac X. laevis Throughout NF stage 23 trigeminal placode pax3.S cdhs, hup2, pax-3, pax3-a, pax3-b, Waardenburg syndrome 1, ws1, xpax3 X. laevis Throughout NF stage 18 neural fold Image source: Published Larger Image Printer Friendly View

Return to previous page